Importance of Inclusion of Representative Populations in Pivotal Clinical Trials: Zolbetuximab as an Example

Y Youngwoo Cho (Committee on Clinical Pharmacology and Pharmacogenomics and Center for Personalized Therapeutics, The University of Chicago, Chicago, IL) A Axel-R. Hanauske (H-Consulting, Hamburg, Germany) M Mark J. Ratain (Committee on Clinical Pharmacology and Pharmacogenomics and Center for Personalized Therapeutics, The University of Chicago, Chicago, IL)

Article Details

Volume / Issue Vol. 1, Issue 1
Published August 05, 2026
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (3)

Y

Youngwoo Cho

Committee on Clinical Pharmacology and Pharmacogenomics and Center for Personalized Therapeutics, The University of Chicago, Chicago, IL

A

Axel-R. Hanauske

H-Consulting, Hamburg, Germany

M

Mark J. Ratain

Committee on Clinical Pharmacology and Pharmacogenomics and Center for Personalized Therapeutics, The University of Chicago, Chicago, IL